Clinical evaluation of subcutaneous immunotherapy with a polymerized molecular allergoid of Alt a 1 in patients with allergic rhinoconjunctivitis and/or allergic asthma caused by the mould Alternaria alternata

Á. Ferrer angelyferrer@gmail.com

Doi
10.23822/EurAnnACI.1764-1489.267

Summary
This is a retrospective analysis of the clinical evolution of 14 patients diagnosed with allergic rhinoconjunctivitis (AR) and/or allergic asthma (AA) caused by Alternaria alternata, who were attended by the allergology service of Vega Baja Hospital of Orihuela (Alicante, Spain). The purpose was to assess the clinical impact and safety of 1-year of subcutaneous immunotherapy with a polymerized molecular allergoid of Alt a 1. Impact of the treatment on allergic diseases (mean number AR/AA episodes and ARIA/GINA classifications), changes in symptoms and prescribed medication, change in the global subjective clinical status of patients and satisfaction with the treatment were also evaluated.

The association between small airway dysfunction and aging: a cross-sectional analysis from the ECOPD cohort

Research - Open Access

Cuiqiong Dai, Fan Wu, Zihui Wang, Jieqi Peng, Huajing Yang, Youlan Zheng, Lifei Lu, Ningning Zhao, Zhishan Deng, Shan Xiao, Xiang Wen, Jianwu Xu, Peiyu Huang, Kunning Zhou, Xiaohui Wu, Yumin Zhou & Pixin Ran

Respiratory Research volume 23, Article number: 229 (2022)

• details

Abstract

Background

Aging has been evidenced to bring about some structural and functional lung changes, especially in COPD. However, whether aging affects SAD, a possible precursor of COPD, has not been well characterized.

Objective

We aimed to comprehensively assess the relationship between aging and SAD from computed tomography, impulse oscillometry, and spirometry perspectives in Chinese.

ALEX versus ISAC multiplex array in analyzing food allergy in atopic children

• Letters to the Editor
• Open Access
• 
  

• Laura J. H. Sonneveld, 
• Joyce A. M. Emons, 
• Nicolette J. T. Arends, 
• Lonneke J. Landzaat, 
• Sharon Veenbergen & 
• Marco W. J. Schreurs 

Clinical and Molecular Allergy volume 20, Article number: 10 (2022) 

Abstract

ALEX multiplex array is a relatively new multiplex allergy test which analyses more than 120 allergen extracts and 170 molecular components. ISAC is the most used and studied multiplex array to date, offering 112 molecular components. In ten atopic children with multiple food allergies good agreement was observed between ALEX and ISAC sIgE results for nearly all shared food components. 

Presence of larger number of allergens in ALEX could help clinicians to improve personalized dietary advice. However more positive sensitizations with unknown clinical relevance were found by ALEX, potentially increasing clinical complexity. Pediatric allergists should be aware of this, especially in young atopic children with (severe) eczema who have not introduced all sorts of food yet.

Download PDF

BSACI guideline for the diagnosis and management of pollen food syndrome in the UK

Clinical Practice Guideline

Free Access

Isabel J. Skypala, Hannah Hunter, Mamidipudi Thirumala Krishna, Helena Rey-Garcia, Stephen J. Till, George du Toit, Elizabeth Angier, Sarah Baker, Kostadin V. Stoenchev, David K. Luyt.

Clin Exp Allergy. 2022; 52: 1018- 1034. doi: 10.1111/cea.14208

Abstract

Pollen food syndrome (PFS) is a highly prevalent food allergy affecting pollen-sensitized children and adults. Sufferers experience allergic symptoms when consuming raw plant foods, due to the homology between the pollen allergens and unstable proteins in these foods. The triggers involved can vary depending on the pollen sensitization, which in turn is affected by geographical location. The British Society of Allergy and Clinical Immunology (BSACI) Standards of Care Committee (SOCC) identified a need to develop a guideline for the diagnosis and management of PFS in the United Kingdom (UK). Guidelines produced by the BSACI use either the GRADE or SIGN methodology; due to a lack of high-quality evidence these recommendations were formulated using the SIGN guidelines, which is acknowledged to be less robust than the GRADE approach. 

Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients

• Research
• Open Access
• 
  

• Takeo Nakajima, 
• Tatsuya Nagano, 
• Yoshiharu Miyata, 
• Shoko Murakami, 
• Satoshi Mitsuyuki, 
• Yohei Funakoshi, 
• Kimikazu Yakushijin, 
• Hitoshi Horimoto, 
• Yoshihiro Nishimura & 
• Kazuyuki Kobayashi 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 78 (2022) 

Abstract

Objectives

Oral corticosteroids reduce the antibody titer of the BNT162b2 mRNA vaccine against SARS-CoV-2. To date, the effect of inhaled corticosteroids on antibody titers is unknown.

Study design

The design of this study is retrospective study.

Methods

We analyzed the relationship between the clinical features and total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in 320 subjects who had never been infected with Coronavirus disease 2019 (COVID-19) and were vaccinated the second time with the BNT162b2 mRNA vaccine between October 1 to December 28, 2021.

Food allergies can be reversed in mice by targeting the microbiome

Although many people with dietary allergies experience mild symptoms when exposed to triggering foods, some face potentially fatal consequences. A bacterial compound called butyrate that’s made by healthy microbiomes has shown promise against allergic reactions in lab tests, but it’s nasty to take orally. Today, scientists describe a more palatable way to deliver this compound and report that their “polymeric micelles” are effective against peanut allergies in mice. The treatment could someday counteract many types of food allergies and inflammatory diseases.

Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines

REVIEW ARTICLE - Free Access

Francisca Palomares, Juan L. Paris, Marina Labella, Inmaculada Doña, Cristobalina Mayorga, María José Torres. Allergy. 2022; 00: 1- 11. doi: 10.1111/all.15461

Abstract

Hypersensitivity reactions to drugs are increasing worldwide. They display a large degree of variability in the immunological mechanisms involved, which impacts both disease severity and the optimal diagnostic procedure.

Sex differences in adult asthma and COPD therapy: a systematic review

• Review
• Open Access
• 
  

• Paola Rogliani, 
• Francesco Cavalli, 
• Beatrice Ludovica Ritondo, 
• Mario Cazzola & 
• Luigino Calzetta 

Respiratory Research volume 23, Article number: 222 (2022) 

• details

Abstract

Background

Although asthma is more prevalent in women and the prevalence of COPD is increasing in women, the current international recommendations for the management and prevention of asthma and COPD provide no sex-related indication for the treatment of these diseases. Therefore, we systematically reviewed the evidence across literature on the sex-related effectiveness of asthma and COPD therapy.

Methods

This systematic review has been registered in PROSPERO and performed according to PRISMA-P. The PICO framework was applied for the literature search strategy: "patient problem” included adult patients suffering from asthma or COPD, “Intervention” regarded the pharmacological treatments for asthma or COPD, “Comparison” was vs. baseline, active controls, or placebo, “Outcome” was any difference sex-related in the effectiveness of interventions.

Results

In asthma 44% of the evidence reported that men responded better than women to the therapy, whereas this percentage was 28% in COPD. ICS was generally less effective in women than in men to treat asthma, and consistent evidence suggests that in asthmatic patients ICS/LABA/LAMA combination may be equally effective in both men and women. Due to the inconsistent available evidence, it is not possible to identify specific treatments whose effectiveness is related to sex difference in COPD patients.

Conclusions

There is a strong need of investigating the sex-related impact of asthma and COPD treatments. Pre-specified analyses in men and women should be planned in future trial protocols, a necessary condition that should be requested also by the regulatory agencies to overcome the anachronistic “one-size-fits-all” approach to therapeutics associated with suboptimal outcomes for patients.

Download PDF